Anteris Technologies Files 8-K

Ticker: AVR · Form: 8-K · Filed: Oct 15, 2025 · CIK: 2011514

Sentiment: neutral

Topics: 8-K, disclosure, corporate-filing

TL;DR

Anteris Tech filed an 8-K on 10/15/25. Standard disclosure.

AI Summary

Anteris Technologies Global Corp. filed an 8-K on October 15, 2025, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Delaware with its principal executive offices in Toowong, Australia, is involved in the orthopedic, prosthetic & surgical appliances & supplies industry.

Why It Matters

This filing indicates routine corporate reporting, including potential financial updates or disclosures relevant to investors tracking the company's regulatory compliance and operational status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for corporate reporting and does not appear to contain any immediately alarming or significant negative news.

Key Numbers

Key Players & Entities

FAQ

What specific items are being disclosed in this 8-K filing?

The filing indicates it covers 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.

When was the earliest event reported in this filing?

The earliest event reported is dated October 15, 2025.

In which state was Anteris Technologies Global Corp. incorporated?

The company was incorporated in Delaware.

What is the primary business classification for Anteris Technologies Global Corp.?

The company falls under 'ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES' with SIC code 3842.

What is the company's principal executive office address?

The principal executive offices are located at Toowong Tower, Level 3, Suite 302, 9 Sherwood Road, Toowong, QLD Australia 4066.

Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-10-15 09:29:18

Key Financial Figures

Filing Documents

01

Item 7.01. Regulation FD Disclosure On October 15, 2025, Anteris Technologies Global Corp. (the "Company") issued a press release regarding the Company obtaining its first European regulatory clearance to commence the DurAVR Transcatheter Heart Valve Global Trial. The information in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 (the "Securities Act") or the Exchange Act, unless such subsequent filing specifically references this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit No. Description 99.1 Press release dated October 15, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Anteris Technologies Global Corp. Date: October 15, 2025 By: /s/ Wayne Paterson Name: Wayne Paterson Title: Vice Chairman and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing